05B4 Leist, Thomas P - Thomas Jefferson University - Thomas Jefferson University
Thomas P. Le
1C84
ist, MD, PhD

Thomas P. Leist, MD, PhD

Contact Dr. Leist

901 Walnut Street
Suite 400
Philadelphia, PA 19107

(215) 955-6871
(215) 503-2990 fax

Most Recent Peer-reviewed Publications

  1. Therapy Optimization in Multiple Sclerosis: A cohort study of therapy adherence and risk of relapse
  2. Therapy optimization in multiple sclerosis: A prospective observational study of therapy compliance and outcomes
  3. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial
  4. Relevance of MOA in MS treatment efficacy
  5. Thomas Leist.
  6. Novel therapeutics in multiple sclerosis management: clinical applications.
  7. Multitasking in multiple sclerosis: Can it inform vocational functioning?
  8. Cladribine: Mode of action and implications for treatment of multiple sclerosis
  9. Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics
  10. Human optic nerve DTI with EPI geometric distortion correction
  11. Thickness of retinal nerve fiber layer correlates with disease duration in parallel with corticospinal tract dysfunction in untreated multiple sclerosis
  12. Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correction
  13. When metals compete: A case of copper-deficiency myeloneuropathy and anemia
  14. Phase Labeling Using Sensitivity encoding (PLUS): Data acquisition and image reconstruction for geometric distortion correction in EPI
  15. Geometric distortion correction in EPI by phase labeling using sensitivity encoding (PLUS)
  16. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up
  17. A phase I trial of interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis (Current Medical Research and Opinion (2006) 22, 9, (1671-1678) DOI: 10.1185/030079906X120931)
  18. The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation
  19. Commentary I: Pathophysiologic construct for neuronal degeneration/ regeneration in multiple sclerosis
  20. Commentary II: Clinical aspects of assessing neuronal health in multiple sclerosis
0